This multicenter, randomized controlled trial is pivotal in evaluating the efficacy and safety of SFRT compared to CRT in treating STS, a malignancy with historically low radiosensitivity. If successful, SFRT could represent a significant advancement in radiotherapy for STS, potentially capturing a share of the oncology market focused on innovative treatment modalities. The trial's outcomes may influence treatment guidelines and establish a competitive edge for the sponsoring institution, Shandong Cancer Hospital and Institute, in the field of radiation oncology. The results could also attract interest from pharmaceutical companies looking to partner on further development or commercialization.